Chemokine receptor 4 and tumors

Abstract

MA Ya-nan, WANG Bao-Hong, XU Xiao-Qun, WANG Jun-Fu. Chemokine receptor 4 and tumors[J]. Journal of International Oncology, 2014, 41(3): 190-193.

［1］ Sauve K, Lepage J, Sanchez M, et al. Positive feedback activation of estrogen receptors by the CXCL12CXCR4 pathway［J］. Cancer Res, 2009, 69(14): 57935800. ［2］ Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: the regulatory link between inflammation and angiogenesis［J］. Trends Immunol, 2004, 25(4): 201209. ［3］ Costantini S, Raucci R, De Vero T, et al. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach［J］. Cytokine, 2013, 10(64): 316321. ［4］ Belmadani A, Tran PB, Ren D, et al. The chemokine stromal cellderived factor1 regulates the migration of sensory neuron progenitors［J］. J Neurosci, 2005, 25(16): 39954003. ［5］ Helbig G, Christopherson KW 2nd, BhatNakshatri P, et al. NFkappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4［J］. J Biol Chem, 2003, 278(24): 2163121638. ［6］ Tomescu O, Xia SJ, Strezlecki D, et al. Inducible shortterm and stable longterm cell culture systems reveal that the PAX3FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression［J］. Lab Invest, 2004, 84(8): 10601070. ［7］ Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas［J］. Oncogene, 2004, 23(35): 59585967. ［8］ Jourdan P, Abbal C, Noraz N, et al. IL4 induces functiongal cellsurface expression of CXCR4 on human T cells［J］. J Immunol, 1998, 160(9): 41534157. ［9］ Jinquan T, Quan S, Jacobi HH, et al. CXC chemokine receptor4 expression and stromal celldrived factor 1αinduced chemotaxis in CD4+ T lymphocytes are regulated by interleukin4 and interleukin10［J］. Immunology, 2000, 99(3): 402410. ［10］ Gupta SK, Lysko PG, Pillarisetti K, et al. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines［J］. J Biol Chem, 1998, 273(7): 42824287. ［11］ MolinaOrtiz I, Bartolomé RA, HernándezVaras P, et al. Overexpression of Ecadherin on melanoma cells inhibits chemokinepromoted invasion involving p190RhoGAP/p120ctndependent inactivation of RhoA［J］. J Biol Chem, 2009, 284(22): 1514715157. ［12］ O′Boyle G, Swidenbnk I, Marshall H, et al. Inhibition of CXCR4CXCL12 chemotaxis in melanoma by AMD11070［J］. Br J Cancer, 2013, 108(8): 16341640. ［13］ Monteagudo C, Ramos D, PellínCarcelén A, et al. CCL27CCR10 and CXCL12CXCR4 chemokine ligandreceptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma［J］. Clin Exp Metastasis, 2012, 29(6): 625637. ［14］ Wang Q, Diao X, Sun J, et al. Regulation of VEGF, MMP9 and metastasis by CXCR4 in a prostate cancer cell line［J］. Cell Biol Int, 2011, 35(9): 897904. ［15］ KühneltLeddihn L, Müller H, Eisendle K, et al. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10?［J］. Arch Dermatol Res, 2012, 304(3): 185193. ［16］ Todaro M, D′Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes［J］. J Immunol, 2009, 182(11): 72877296. ［17］ Kim H. Will the stromaderived factor1alpha (CXCL12)/CXCR4 pathway become a major concern for advanced colorectal cancer?［J］. J Korean Soc Coloproctol, 2012, 28(1): 34. ［18］ Abedini F, Hosseinkhani H, Ismail M, et al. Cationized dextran nanoparticleencapsulated CXCR4siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer［J］. Int J Nanomedicine, 2012, 7: 41594168. ［19］ Hu T, Yao Y, Yu S, et al. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer［J］. J Biomed Res, 2013, 27(4): 283290. ［20］ Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment［J］. Blood, 2006, 107(5): 17611767. ［21］ Boudot A, Kerdivel G, Habauzit D, et al. Differential estrogenregulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells［J］. PLoS One, 2011, 6(6): e20898. ［22］ Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells［J］. Cell Death Differ, 2009, 16(5): 664673. ［23］ Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer［J］. Cancer Res, 2011, 71(16): 55225534. ［24］ Hall JM, Korach KS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ERCXCL12CXCR4 signaling axis［J］. Mol Carcinog, 2013, 52(9): 715725. ［25］ Wang J, Cai J, Han F, et al. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway［J］. Int J Gynecol Cancer, 2011, 21(6): 981987. ［26］ Li X, Ma Q, Xu Q, et al. SDF1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelialmesenchymal transition in vitro through noncanonical activation of Hedgehog pathway［J］. Cancer Lett, 2012, 322(2): 169176. ［27］ Dai X, Mao Z, Huang J, et al. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of nonsmall cell lung cancer in vitro［J］. Oncol Lett, 2013, 5(1): 277282. ［28］ Wanger PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma［J］. Ann Surg Oncol, 2008, 15(10): 28332841. ［29］ Yuan L, Zhang H, Liu J, et al. Growth factor receptorSrcmediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration［J］. Mol Cancer, 2013, 12: 18.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[5]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin.Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.
[7]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[8]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[9]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.
[10]	Wang Bin, Zhou Jiangyun, Liu Xi.Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(8): 484-488.
[11]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng.Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(12): 755-759.
[12]	Dai Ang, Sun Qing.CRYAB and tumors[J]. Journal of International Oncology, 2020, 47(6): 351-354.
[13]	Yang Chao, Wang Jianbo, Zhang Juhong, Wang Jialong.Overexpression of miR-125 inhibits proliferation and invasion of nasopharyngeal carcinoma cells by down-regulating FGF-2[J]. Journal of International Oncology, 2020, 47(5): 257-263.
[14]	Zhang Yanqiang, Zhang Yang, Li Chunhua, Zhang Dianping, Liu Baoguo, Peng Xiangeng.High mobility group protein B1 and breast cancer[J]. Journal of International Oncology, 2020, 47(5): 297-300.
[15]	Li Kaichun, Wang Yajie.Current status of clinical researches on metastatic triple negative breast cancer[J]. Journal of International Oncology, 2020, 47(3): 169-173.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments